Iovance Biotherapeutics’ (IOVA) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Iovance Biotherapeutics (NASDAQ:IOVA) in a research note issued to investors on Friday,Benzinga reports. HC Wainwright currently has a $32.00 price objective on the biotechnology company’s stock. HC Wainwright also issued estimates for Iovance Biotherapeutics’ Q1 2025 earnings at ($0.23) EPS and Q4 2025 earnings at ($0.13) EPS.

Separately, Piper Sandler reduced their price objective on Iovance Biotherapeutics from $10.00 to $7.50 and set a “neutral” rating for the company in a research note on Friday, January 31st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $20.50.

Iovance Biotherapeutics Price Performance

NASDAQ IOVA opened at $4.24 on Friday. The business has a 50 day simple moving average of $6.27 and a 200 day simple moving average of $8.62. Iovance Biotherapeutics has a one year low of $3.62 and a one year high of $18.24. The stock has a market capitalization of $1.29 billion, a P/E ratio of -2.85 and a beta of 0.53.

Iovance Biotherapeutics (NASDAQ:IOVA) last announced its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.26) EPS for the quarter, meeting analysts’ consensus estimates of ($0.26). Iovance Biotherapeutics had a negative return on equity of 58.43% and a negative net margin of 451.25%. The firm had revenue of $73.69 million during the quarter, compared to analysts’ expectations of $72.17 million. Equities analysts expect that Iovance Biotherapeutics will post -1.24 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of IOVA. Creative Planning lifted its holdings in shares of Iovance Biotherapeutics by 2.6% in the third quarter. Creative Planning now owns 73,489 shares of the biotechnology company’s stock valued at $690,000 after purchasing an additional 1,896 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Iovance Biotherapeutics by 31.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,978 shares of the biotechnology company’s stock valued at $105,000 after purchasing an additional 2,624 shares in the last quarter. Rice Hall James & Associates LLC lifted its holdings in shares of Iovance Biotherapeutics by 2.6% in the third quarter. Rice Hall James & Associates LLC now owns 1,679,157 shares of the biotechnology company’s stock valued at $15,767,000 after purchasing an additional 43,132 shares in the last quarter. Creative Financial Designs Inc. ADV lifted its holdings in shares of Iovance Biotherapeutics by 59.3% in the third quarter. Creative Financial Designs Inc. ADV now owns 21,740 shares of the biotechnology company’s stock valued at $204,000 after purchasing an additional 8,090 shares in the last quarter. Finally, Farther Finance Advisors LLC lifted its holdings in shares of Iovance Biotherapeutics by 142.3% in the third quarter. Farther Finance Advisors LLC now owns 15,389 shares of the biotechnology company’s stock valued at $145,000 after purchasing an additional 9,037 shares in the last quarter. Institutional investors own 77.03% of the company’s stock.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.